2012
Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting
Gandhi N, Andrews J, Brust J, Montreuil R, Weissman D, Heo M, Moll A, Friedland G, Shah N. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. The International Journal Of Tuberculosis And Lung Disease 2012, 16: 90-97. PMID: 22236852, PMCID: PMC3302205, DOI: 10.5588/ijtld.11.0153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntitubercular AgentsCD4 Lymphocyte CountCoinfectionDrug Resistance, Multiple, BacterialExtensively Drug-Resistant TuberculosisFemaleHIV InfectionsHumansMaleMarkov ChainsMonte Carlo MethodPrevalencePrognosisProportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsSouth AfricaSurvival AnalysisTime FactorsTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryConceptsHuman immunodeficiency virusXDR-TB patientsRisk factorsAntiretroviral therapyXDR-TBDrug-resistant (XDR) TBImmunosuppressed human immunodeficiency virusStrong independent risk factorHigh HIV prevalence settingsMDR-TB patientsTB treatment programsIndependent risk factorYear of diagnosisDrug-resistant tuberculosisHIV prevalence settingsCells/Principal risk factorsCase-control studyAmplification of resistanceHigh mortality rateART initiationHIV testingImmunodeficiency virusPrevalence settingsMortality rate
2008
Episodic Antiretroviral Therapy Increases HIV Transmission Risk Compared With Continuous Therapy: Results of a Randomized Controlled Trial
Burman W, Grund B, Neuhaus J, Douglas J, Friedland G, Telzak E, Colebunders R, Paton N, Fisher M, Rietmeijer C. Episodic Antiretroviral Therapy Increases HIV Transmission Risk Compared With Continuous Therapy: Results of a Randomized Controlled Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2008, 49: 142-150. PMID: 18769356, PMCID: PMC2749067, DOI: 10.1097/qai.0b013e318183a9ad.Peer-Reviewed Original ResearchConceptsHIV transmission riskHigh-risk behaviorsEpisodic antiretroviral therapyAntiretroviral therapyTransmission riskContinuous antiretroviral therapyHIV RNA levelsAntiretroviral Therapy studyProportion of participantsTherapy armContinuous therapyControlled TrialsRandomized armHIV transmissionMean ageNeedle sharingPatientsTherapyTherapy studiesStrategy of managementRNA levelsSexual activityRiskBaselineLaboratory testing
2006
Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments
Fiellin DA, Friedland GH, Gourevitch MN. Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments. Clinical Infectious Diseases 2006, 43: s173-s177. PMID: 17109303, DOI: 10.1086/508180.BooksConceptsOpioid agonist treatmentOpioid dependenceAgonist treatmentHuman immunodeficiency virus (HIV) transmissionBuprenorphine/naloxone combinationNeurobiological basisOpioid withdrawalBuprenorphine treatmentHIV infectionDecreased riskNaloxone combinationOpioid receptorsGeneral physiciansMedical disordersNew treatmentsMethadoneVirus transmissionBuprenorphineTreatmentMedicationsPatientsChronicInfectionIntracellular processesPhysiciansInteractions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine
McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine. Clinical Infectious Diseases 2006, 43: s224-s234. PMID: 17109309, DOI: 10.1086/508187.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesArea Under CurveBenzoxazinesBuprenorphineCase-Control StudiesCohort StudiesCyclopropanesDelavirdineDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHIV InfectionsHumansMaleNarcotic AntagonistsOpioid-Related DisordersOxazinesProbabilityPrognosisReference ValuesReverse Transcriptase InhibitorsRisk AssessmentStatistics, NonparametricTreatment OutcomeConceptsNonnucleoside reverse transcriptase inhibitor efavirenzReverse transcriptase inhibitor efavirenzInhibitor efavirenzPharmacokinetics of buprenorphineOpiate withdrawal symptomsAdjustment of dosesEffects of buprenorphineHuman immunodeficiency virusConcentration-time curveOpioid-dependent participantsHealthy control participantsAntiretroviral administrationAdverse eventsAgonist medicationsHIV diseaseNegative volunteersStandard dosesOpioid dependenceImmunodeficiency virusBuprenorphine concentrationsWithdrawal symptomsAntiretroviral pharmacokineticsDrug interactionsOpiate dependenceBuprenorphineInteractions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir
McCance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir. Clinical Infectious Diseases 2006, 43: s235-s246. PMID: 17109310, DOI: 10.1086/508188.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineCase-Control StudiesCohort StudiesDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHIV Protease InhibitorsHIV SeronegativityHumansLopinavirMaleNarcotic AntagonistsNelfinavirOpioid-Related DisordersProbabilityPyrimidinonesReference ValuesRisk AssessmentRitonavirConceptsLPV/rLopinavir/ritonavirProtease inhibitor nelfinavirOpioid dependenceAdministration of ritonavirOpioid partial agonistAdjustment of dosesHuman immunodeficiency virusConcentration-time curveHealthy control participantsPI administrationPI pharmacokineticsHIV diseaseNegative volunteersImmunodeficiency virusOpiate withdrawalDrug interactionsBuprenorphineRitonavirPartial agonistNelfinavirControl participantsPharmacokinetic studyAdministrationSignificant increase